| MeSH term | MeSH ID | Detail |
|---|---|---|
| Vascular Calcification | D061205 | 1 associated lipids |
| Angioid Streaks | D000793 | 1 associated lipids |
| Rupture, Spontaneous | D012422 | 1 associated lipids |
| Malocclusion, Angle Class I | D008311 | 1 associated lipids |
| Hyperostosis | D015576 | 1 associated lipids |
| Hip Dislocation | D006617 | 1 associated lipids |
| Hyperparathyroidism, Primary | D049950 | 1 associated lipids |
| Breast Neoplasms, Male | D018567 | 1 associated lipids |
| Severe Combined Immunodeficiency | D016511 | 1 associated lipids |
| Peri-Implantitis | D057873 | 1 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Okada T et al. | Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. | 2003 | Clin. Exp. Metastasis | pmid:14669795 |
| Gannagé-Yared MH et al. | Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. | 2003 | J. Endocrinol. Invest. | pmid:14669830 |
| Ashcroft AJ et al. | Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. | 2003 | Immunity | pmid:14670302 |
| Chong B et al. | Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. | 2003 | J. Bone Miner. Res. | pmid:14672344 |
| Teitelbaum SL and Ross FP | Genetic regulation of osteoclast development and function. | 2003 | Nat. Rev. Genet. | pmid:12897775 |
| Nielsen KL et al. | Biglycan deficiency interferes with ovariectomy-induced bone loss. | 2003 | J. Bone Miner. Res. | pmid:14672350 |
| Si AI et al. | Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. | 2003 | J. Cell. Biochem. | pmid:12898514 |
| Nitta K et al. | The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. | 2003 | Am. J. Kidney Dis. | pmid:12900812 |
| Amizuka N et al. | Defective bone remodelling in osteoprotegerin-deficient mice. | 2003 | J Electron Microsc (Tokyo) | pmid:14756238 |
| Fizazi K et al. | Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. | 2003 | Clin. Cancer Res. | pmid:12855635 |
| Kawana F and Sasaki T | Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. | 2003 | J Electron Microsc (Tokyo) | pmid:14756239 |
| Okuma K et al. | Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. | 2003 | J. Virol. | pmid:12857926 |
| Cheng X et al. | The TNF receptor superfamily: role in immune inflammation and bone formation. | 2003 | Immunol. Res. | pmid:12857975 |
| Shin MM et al. | High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. | 2003 | Exp. Mol. Med. | pmid:12858015 |
| Gehrke T et al. | Receptor activator of nuclear factor kappaB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. | 2003 | Scand. J. Rheumatol. | pmid:14690142 |
| Glossop JR et al. | No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. | 2003 | J. Rheumatol. | pmid:12858434 |
| Hampson G et al. | Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. | 2003 | Osteoporos Int | pmid:12904840 |
| Stolina M et al. | Regulatory effects of osteoprotegerin on cellular and humoral immune responses. | 2003 | Clin. Immunol. | pmid:14697750 |
| Misra M et al. | Serum osteoprotegerin in adolescent girls with anorexia nervosa. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915674 |
| Lonergan M et al. | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12915677 |
| Kapczuk K et al. | [Osteoprotegerin/RANKL/RANK system and postmenopausal osteoporosis. The possible therapeutic aspects]. | 2003 | Ginekol. Pol. | pmid:12916277 |
| Liu JZ et al. | [Co-expression of human bone morphogenetic protein-2 and osteoprotegerin in myoblast C2C12]. | 2003 | Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi | pmid:12916296 |
| Bendre MS et al. | Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. | 2003 | Bone | pmid:12919697 |
| Tabb MM et al. | Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. | 2003 | J. Biol. Chem. | pmid:12920130 |
| Park HR et al. | Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. | 2003 | J. Korean Med. Sci. | pmid:12923331 |
| Paloneva J et al. | DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. | 2003 | J. Exp. Med. | pmid:12925681 |
| Fukushima H et al. | Expression and role of RANKL in periodontal ligament cells during physiological root-resorption in human deciduous teeth. | 2003 | Eur. J. Oral Sci. | pmid:12887401 |
| Ito R et al. | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | 2003 | Virchows Arch. | pmid:12838418 |
| Smith MD et al. | Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. | 2003 | Ann. Rheum. Dis. | pmid:12634226 |
| Sakurai A et al. | Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. | 2003 | Infect. Immun. | pmid:14500523 |
| Kim HH et al. | RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. | 2003 | FASEB J. | pmid:14500543 |
| Nakamura M et al. | Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. | 2003 | Endocrinology | pmid:14500574 |
| Zhang Z et al. | Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. | 2003 | J. Immunol. | pmid:14500659 |
| Ueno Y et al. | In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. | 2003 | J. Cell. Biochem. | pmid:14505343 |
| Kaneyama K et al. | Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. | 2003 | Int J Oral Maxillofac Surg | pmid:14505625 |
| Miyahira Y et al. | Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination. | 2003 | J. Immunol. | pmid:14662831 |
| Seidlova-Wuttke D et al. | Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimicifuga racemosa) extract: comparison with estradiol-17beta. | 2003 | Eur. J. Endocrinol. | pmid:14514351 |
| Hortobagyi GN | Novel approaches to the management of bone metastases. | 2003 | Semin. Oncol. | pmid:14613037 |
| Voskaridou E et al. | Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. | 2003 | Br. J. Haematol. | pmid:14616979 |
| Uemura H et al. | Circulating osteoprotegerin in women during GnRH-agonist treatment and their relationships with mineral components and biomarkers of bone turnover. | 2003 | Bone | pmid:14623063 |
| Grigorie D et al. | Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. | 2003 | Rom J Intern Med | pmid:15526523 |
| Ren W et al. | Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. | 2003 | Biomaterials | pmid:14530078 |
| Wiethe C et al. | Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. | 2003 | J. Immunol. | pmid:14530334 |
| Wagner EF and Matsuo K | Signalling in osteoclasts and the role of Fos/AP1 proteins. | 2003 | Ann. Rheum. Dis. | pmid:14532157 |
| Ueland T et al. | Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. | 2003 | Bone | pmid:14555269 |
| Schoppet M et al. | Increased osteoprotegerin serum levels in men with coronary artery disease. | 2003 | J. Clin. Endocrinol. Metab. | pmid:12629080 |
| Nagata N et al. | Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. | 2003 | Bone | pmid:14555278 |
| Han W et al. | Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. | 2003 | Biotechnol. Appl. Biochem. | pmid:12630898 |
| Koshihara Y et al. | Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture. | 2003 | J. Endocrinol. | pmid:12630919 |
| Grimaud E et al. | Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. | 2003 | Am. J. Pathol. | pmid:14578201 |
| Alvarez L et al. | Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. | 2003 | Arthritis Rheum. | pmid:12632438 |
| Bord S et al. | The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. | 2003 | Bone | pmid:12633785 |
| Coen G et al. | Serum leptin in dialysis renal osteodystrophy. | 2003 | Am. J. Kidney Dis. | pmid:14582047 |
| Garber K | Why it hurts: researchers seek mechanisms of cancer pain. | 2003 | J. Natl. Cancer Inst. | pmid:12783923 |
| Chagraoui H et al. | Expression of osteoprotegerin mRNA and protein in murine megakaryocytes. | 2003 | Exp. Hematol. | pmid:14585373 |
| Liu B et al. | Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. | 2003 | J. Oral Pathol. Med. | pmid:12787044 |
| Eaton CL and Coleman RE | Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. | 2003 | Cancer Treat. Rev. | pmid:12787713 |
| Fahrleitner-Pammer A et al. | Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. | 2003 | Wien. Klin. Wochenschr. | pmid:12793029 |
| Dovio A et al. | Correspondence re: A. Lipton et al., Serum osteoprotegerin levels in healthy controls and cancer patients. Clin. Cancer Res., 8: 2306-2310, 2002. | 2003 | Clin. Cancer Res. | pmid:12796409 |
| Flick LM et al. | Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. | 2003 | J. Orthop. Res. | pmid:12798068 |
| Khapli SM et al. | IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-kappa B ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage. | 2003 | J. Immunol. | pmid:12816992 |
| Kawase Y et al. | Bone malformations in interleukin-18 transgenic mice. | 2003 | J. Bone Miner. Res. | pmid:12817749 |
| Kikuchi T et al. | Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. | 2003 | J. Dent. Res. | pmid:12821717 |
| D'Elia HF et al. | Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. | 2003 | Arthritis Res. Ther. | pmid:12823855 |
| Knudsen ST et al. | Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. | 2003 | Eur. J. Endocrinol. | pmid:12824864 |
| Kaneyama K et al. | Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. | 2003 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:12973279 |
| Lee ZH and Kim HH | Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. | 2003 | Biochem. Biophys. Res. Commun. | pmid:12745060 |
| Boyle WJ et al. | Osteoclast differentiation and activation. | 2003 | Nature | pmid:12748652 |
| Terpos E et al. | Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. | 2003 | Blood | pmid:12689925 |
| Zheng B et al. | MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. | 2003 | Blood | pmid:12689928 |
| Moreno JL et al. | IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. | 2003 | Blood | pmid:12689929 |
| Dovio A et al. | Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. | 2003 | J. Endocrinol. | pmid:12697042 |
| Nakano M et al. | Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. | 2003 | Oral Dis | pmid:12657033 |
| Ra JS et al. | Osteoprotegerin inhibits proliferation of myeloid progenitor cells. | 2003 | J. Hematother. Stem Cell Res. | pmid:12662434 |
| Szalay F et al. | High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. | 2003 | J. Hepatol. | pmid:12663228 |
| Okada Y et al. | Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone. | 2003 | J. Biol. Chem. | pmid:12665515 |
| Bell NH | RANK ligand and the regulation of skeletal remodeling. | 2003 | J. Clin. Invest. | pmid:12697730 |
| Eghbali-Fatourechi G et al. | Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. | 2003 | J. Clin. Invest. | pmid:12697741 |
| Enomoto H et al. | Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene. | 2003 | J. Biol. Chem. | pmid:12697767 |
| Nakashima T et al. | RANKL and RANK as novel therapeutic targets for arthritis. | 2003 | Curr Opin Rheumatol | pmid:12707582 |
| Johnson-Pais TL et al. | Determination of a minimal region of loss of heterozygosity on chromosome 18q21.33 in osteosarcoma. | 2003 | Int. J. Cancer | pmid:12673693 |
| Zaidi M et al. | Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. | 2003 | J. Bone Miner. Res. | pmid:12674320 |
| Tanaka S et al. | Signal transduction pathways regulating osteoclast differentiation and function. | 2003 | J. Bone Miner. Metab. | pmid:12720046 |
| Kato I et al. | TRANCE together with IL-7 induces pre-B cells to proliferate. | 2003 | Eur. J. Immunol. | pmid:12548564 |
| Sordillo EM and Pearse RN | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. | 2003 | Cancer | pmid:12548579 |
| Oyajobi BO and Mundy GR | Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. | 2003 | Cancer | pmid:12548580 |
| Croucher PI et al. | Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. | 2003 | Cancer | pmid:12548581 |
| Lipton A | Bisphosphonates and metastatic breast carcinoma. | 2003 | Cancer | pmid:12548585 |
| Demers LM | Bone markers in the management of patients with skeletal metastases. | 2003 | Cancer | pmid:12548589 |
| Body JJ et al. | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. | 2003 | Cancer | pmid:12548591 |
| Xing L et al. | Expression of either NF-kappaB p50 or p52 in osteoclast precursors is required for IL-1-induced bone resorption. | 2003 | J. Bone Miner. Res. | pmid:12568403 |
| Cao J et al. | Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice. | 2003 | J. Bone Miner. Res. | pmid:12568404 |
| Johnson-Pais TL et al. | Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. | 2003 | J. Bone Miner. Res. | pmid:12568416 |
| Clohisy JC et al. | RANKL is an essential cytokine mediator of polymethylmethacrylate particle-induced osteoclastogenesis. | 2003 | J. Orthop. Res. | pmid:12568950 |
| Liu JZ et al. | [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. | 2003 | Sheng Wu Gong Cheng Xue Bao | pmid:15969033 |
| Fahrleitner A et al. | Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. | 2003 | Bone | pmid:12584041 |
| Lanzi R et al. | GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults. | 2003 | Eur. J. Endocrinol. | pmid:12590637 |
| Shipman CM and Croucher PI | Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. | 2003 | Cancer Res. | pmid:12615702 |
| Haynes DR et al. | Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. | 2003 | Rheumatology (Oxford) | pmid:12509625 |
| Rude RK et al. | Magnesium deficiency: effect on bone and mineral metabolism in the mouse. | 2003 | Calcif. Tissue Int. | pmid:12370796 |